PSMA PET/CT Access Lags Behind Guideline-Recommended Use in Europe, Exploratory Data Show

Real-world access to PSMA PET/CT for prostate cancer remains below estimated eligible populations in staging and biochemical recurrence, with wide variation between countries. Barriers include reimbursement, capacity, logistics, and non-standardised referral pathways.

• Exploratory modelling and Spanish market research indicated that use remains below the likely eligible population, though these are implementation signals rather than definitive prevalence estimates.
• Reported barriers encompass reimbursement and local approval requirements, PET/CT and nuclear medicine capacity, radiopharmaceutical logistics, non-standardised referral pathways, waiting times, and institutional variation.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.